Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors

Andreas Helisch; Clemens Kratochwil; Christian Kleist; Susanne Krämer; Juan Jose Rosales Castillo; Katharina Dendl; Hendrik Rathke; Isabelle von Goetze; Mathias Schreckenberger; Dirk Jäger; Thomas Lindner; Walter Mier; Frederik Giesel; Uwe Haberkorn; Manuel Röhrich

doi:10.2967/jnumed.124.268386

Research ArticleClinical Investigation

Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with ²¹³Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors

Andreas Helisch, Clemens Kratochwil, Christian Kleist, Susanne Krämer, Juan Jose Rosales Castillo, Katharina Dendl, Hendrik Rathke, Isabelle von Goetze, Mathias Schreckenberger, Dirk Jäger, Thomas Lindner, Walter Mier, Frederik Giesel, Uwe Haberkorn and Manuel Röhrich

Journal of Nuclear Medicine October 2024, jnumed.124.268386; DOI: https://doi.org/10.2967/jnumed.124.268386

Andreas Helisch

1Department of Nuclear Medicine, University Medical Center, Mainz, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Clemens Kratochwil

2Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

3German Center of Lung Research, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christian Kleist

2Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Susanne Krämer

2Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Juan Jose Rosales Castillo

4Department of Nuclear Medicine, University Clinic of Navarra, Pamplona, Spain;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Katharina Dendl

2Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hendrik Rathke

2Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

5Department of Radiology, Cantonal Hospital Graubünden, Chur, Switzerland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Isabelle von Goetze

1Department of Nuclear Medicine, University Medical Center, Mainz, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mathias Schreckenberger

1Department of Nuclear Medicine, University Medical Center, Mainz, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Dirk Jäger

6Department of Medical Oncology, Heidelberg University Hospital, National Center for Tumor Diseases, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thomas Lindner

2Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

7Evergreen Theragnostics, Springfield, New Jersey;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Walter Mier

2Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Frederik Giesel

2Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

8Department of Nuclear Medicine, University Hospital, Düsseldorf, Germany; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Uwe Haberkorn

2Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

3German Center of Lung Research, Heidelberg, Germany;

9Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Manuel Röhrich

1Department of Nuclear Medicine, University Medical Center, Mainz, Germany;

2Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;

3German Center of Lung Research, Heidelberg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 66, Issue 5

May 1, 2025

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with ²¹³Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors

Journal of Nuclear Medicine Oct 2024, jnumed.124.268386; DOI: 10.2967/jnumed.124.268386

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Journal of Nuclear Medicine Oct 2024, jnumed.124.268386; DOI: 10.2967/jnumed.124.268386

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

FAPI
radiopharmaceutical therapy
bismuth
α-therapy
targeted therapy

Main menu

User menu

Search

Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with ²¹³Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords